Magnesium supplementation as an adjunct to fluoxetine therapy for depression.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Consecutive patients aged 18 to 45 years who had been prescribed fluoxetine therapy for new-onset or chronic depression were recruited between November 2024 and February 2025 at the outpatient psychiatry clinic of Wahidin Sudirohusodo General Hospital and three affiliated hospitals in Makassar, Indonesia.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Outcomes were assessed at baseline and week 6.

The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS).

Blood samples were collected to measure serum serotonin levels.

What Was Measured

The subject headings attached to it are Depression, Dietary Supplements, Fluoxetine, Magnesium and Serotonin.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan), a journal based in China.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.